Compugen ltd (CGEN)
Balance Sheet / Yearly
Jun'18Dec'17Jun'17Dec'16Jun'16Dec'15Jun'15Dec'14Jun'14Dec'13Jun'13Dec'12Jun'12Dec'11Dec'10
ASSETS
CURRENT ASSETS:
Cash and cash equivalents

10,305

25,470

16,914

9,709

19,325

10,777

9,581

25,643

103,244

28,751

13,094

16,374

8,787

5,846

7,300

Restricted cash

634

1,050

1,047

993

992

1,077

546

543

155

154

99

96

91

92

684

Short-term bank deposits

32,151

3,918

28,150

50,825

53,761

69,567

85,526

47,142

10,015

18,015

15,015

3,215

13,107

16,525

14,524

Investment in marketable securities

-

-

-

-

104

426

-

1,054

-

-

-

-

-

-

-

Trade receivable

-

-

-

-

400

7,800

-

-

1,140

-

-

-

-

-

21

Investment in Evogene

-

-

-

-

-

-

997

-

1,858

4,565

4,713

5,196

-

0

-

Other accounts receivable and prepaid expenses

1,282

741

1,433

1,153

1,332

1,352

1,474

716

757

1,731

736

690

650

546

548

Receivables from funding arrangement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,000

Total current assets

44,372

31,179

47,544

62,680

75,914

90,999

98,124

75,098

117,169

53,216

33,657

25,571

22,635

23,009

28,077

NON-CURRENT ASSETS:
Long-term bank deposits

-

-

-

-

-

-

-

35,026

2,256

0

1,922

1,728

6,257

5,575

7,801

Long-term prepaid expenses

136

110

40

92

96

101

99

108

107

158

201

360

400

0

64

Long-term lease deposits

-

-

-

-

-

-

-

-

-

-

22

-

68

-

-

Investment in Evogene

-

-

-

-

-

-

-

-

-

-

-

-

4,662

4,093

6,227

Long-term lease deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

17

-

Severance pay fund

2,563

2,810

2,775

2,402

2,281

2,179

2,171

2,024

2,256

2,129

1,900

1,728

1,527

1,465

1,510

Property and equipment, net

3,967

4,647

5,265

5,965

6,169

6,028

2,863

2,730

2,009

1,208

1,226

1,250

696

497

580

Total non- current assets

6,666

7,567

8,080

8,459

8,546

8,308

5,133

39,888

-

3,495

-

-

-

-

-

Total assets

51,038

38,746

55,624

71,139

84,460

99,307

103,257

114,986

121,541

56,711

37,006

28,909

29,988

29,081

36,458

LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables

1,756

3,445

2,120

1,274

1,312

2,001

1,209

1,493

1,330

693

857

443

335

248

507

Deferred revenue

-

-

-

-

123

312

1,053

1,789

3,121

5,318

-

0

-

-

-

Research and development funding arrangement

-

-

-

-

-

-

210

421

-

0

-

-

-

-

-

Other accounts payable and accrued expenses

5,741

2,749

2,947

3,466

3,103

4,541

2,781

2,886

2,362

1,728

1,219

941

1,207

1,175

1,934

Total current liabilities

7,497

6,194

5,067

4,740

4,538

6,854

5,253

6,589

6,813

7,739

2,076

1,384

1,542

1,423

2,441

NON-CURRENT LIABILITIES:
Research and development funding arrangement

-

-

-

-

-

-

-

-

-

13,189

-

-

-

-

-

Research and development funding arrangement

-

-

-

-

-

-

-

-

13,074

-

12,037

-

4,793

6,434

4,037

Research and development funding arrangements and others

-

-

-

-

-

-

-

-

-

-

-

7,872

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

948

1,454

-

0

-

-

-

Accrued severance pay

2,994

3,255

3,333

2,880

2,789

2,556

2,590

2,281

2,577

2,441

2,179

1,981

1,766

1,643

1,695

Total non-current liabilities

2,994

3,255

3,333

2,880

2,789

2,556

2,590

2,281

16,599

17,084

14,216

9,853

6,559

8,077

5,732

COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 7)

0

0

0

0

0

0

0

0

0

0

-

0

-

-

0

SHAREHOLDERS' EQUITY:
Share capital: Ordinary shares of NIS 0.01 par value: 100,000,000 shares authorized at June 30, 2018 and December 31, 2017; 57,197,029 and 51,293,070 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively

157

140

140

140

139

138

138

137

132

111

104

99

97

94

92

Additional paid-in capital

358,721

337,382

335,819

334,337

331,538

328,797

326,304

324,053

308,531

235,351

216,304

206,325

202,193

195,714

190,275

Accumulated other comprehensive income

0

17

326

7

148

421

1,219

1,222

1,885

4,628

4,838

5,367

4,833

4,264

6,405

Accumulated deficit

-318,331

-308,242

-289,061

-270,965

-254,692

-239,459

-232,247

-219,296

-212,419

-208,202

-200,532

-194,119

-185,236

-180,491

-168,487

Total shareholders' equity

40,547

29,297

47,224

63,519

77,133

89,897

95,414

106,116

98,129

31,888

20,714

17,672

21,887

19,581

28,285

Total liabilities and shareholders' equity

51,038

38,746

55,624

71,139

84,460

99,307

103,257

114,986

121,541

56,711

37,006

28,909

29,988

29,081

36,458